Gemini-enabled monoclonal antibodies for malaria

Gemini-enabled monoclonal antibodies for malaria refer to a new generation of antibody therapeutics developed using the Gemini platform, which is designed to enhance the durability, expression, and dosing profile of biologic drugs. These monoclonal antibodies are engineered specifically to target malaria parasites—most commonly Plasmodium falciparum—by binding to key antigens such as the circumsporozoite protein (CSP) on sporozoites. The Gemini technology aims to provide longer-lasting protection with reduced dosing frequency compared to conventional antibody therapies. This approach builds upon recent advances in anti-malarial mAbs that have shown high efficacy in both clinical trials and field studies, offering a promising strategy for both prophylactic and potentially therapeutic use against malaria[3][1][2]. The primary developer associated with this technology is Eyam Health[3].